Abstract
The potential for reutericyclin derivatives to be used as topical antibiotics to treat staphylococcal skin infections was investigated. All reutericyclins inhibited the growth of clinical isolates of drug-resistant Staphylococcus aureus. Unlike the standard topical agent mupirocin, most reutericyclin derivatives eradicated staphylococcal biofilms. Moreover, two compounds formulated in hydrophilic petrolatum (10%, wt/wt) were efficacious in treating S. aureus superficial skin infections in mice. These data exemplify the prospect of developing reutericyclins as new topical antibiotics.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / chemistry
-
Anti-Bacterial Agents / pharmacology
-
Anti-Bacterial Agents / therapeutic use*
-
Biofilms / drug effects
-
Cell Line
-
Fibroblasts / cytology
-
Fibroblasts / drug effects
-
Humans
-
Male
-
Mice
-
Pyrrolidinones / pharmacology
-
Pyrrolidinones / therapeutic use
-
Staphylococcal Skin Infections / drug therapy*
-
Tenuazonic Acid / analogs & derivatives
-
Tenuazonic Acid / chemistry
-
Tenuazonic Acid / pharmacology
-
Tenuazonic Acid / therapeutic use
Substances
-
Anti-Bacterial Agents
-
Pyrrolidinones
-
reutericyclin
-
tetramic acid
-
Tenuazonic Acid